top of page

Study Shows SpotitEarly's
High Accuracy

The Rainbow Study, a large-scale observational double blind clinical performance trial, measured the effectiveness and accuracy of SpotitEarly’s breath test in detecting the 4 most common types of cancer at various stages, using breath samples.

93-9.png

Sensitivity

94-3.png

Specificity

4 Types of Cancer Targeted:

Lung, Breast, Prostate, Colorectal

3

Medical Centers

1,386

Participants

338

Cancer positives

1,048

Controls

The Rainbow Study is the first clinical performance trial of its kind, using a bio-hybrid platform powered by AI to detect cancer in breath samples. Its results show outstanding accuracy by all measures, and across cancer stages, even the earliest ones, when it really counts. 

The study, led by Prof. Nadir Arber Director of the Integrated Cancer Prevention Center (ICPC) at Tel Aviv Sourasky Medical Center, was conducted at three prominent medical centers.

Clinical Partners

University

of Pennsylvania

Tel Aviv Sourasky

Medical Center

Hadassah

Medical Center

Rambam Health

Care Campus

Assuta

Hospital

Impressive Sensitivity in Early Stages 1 & 2

Clinical Study Program

The Pink Study

The Pink study is an ongoing clinical performance trial dedicated to the early detection of Breast cancer. Our researchers are actively working to develop innovative methods to detect Breast cancer at its earliest stages, where treatment options are most effective, while helping prevent unnecessary intervention and stress.

This trial is being conducted in cooperation with the University of Pennsylvania (UPenn) and the Tel- Aviv Sourasky Medical Center

Enrolling

The White Study

The White study is another ongoing clinical performance trial focused on early detection of Lung cancer. Our dedicated team of scientists and medical professionals are striving to develop advanced techniques to identify Lung cancer in its early stages, leading to improved outcomes for more patients while relieving some of the burden on healthcare systems.

Learn more about how SpotitEarly could help save more lives

SpotitEarly’s performance has demonstrated:

  • High accuracy across 4 cancer types the system was trained for, as well as in multiple others

  • Very high sensitivity and confidence level in the early stages of cancer

bottom of page